Tibotec Expands Access Program for HIV Research (RedNova)
Tibotec Pharmaceuticals has expanded its access program for TMC125, its investigational agent developed to combat resistant strains of the HIV virus. The program has opened in the US and will open shortly in Canada and Europe, subject to the necessary approvals.

Panel slams FDA's internal politics, lack of follow-up for approved drugs (EARTHtimes.org)
The US Food and Drug Administration (FDA) needs reforms to better ensure the safety of medicines, go easy on approvals of new medicines and study in-depth the side effects of post-approval drugs. These are only some of the recommendations that a panel empowered by the FDA has come up with to make the drugs regulator efficient.